THE INVESTOR

▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald

Bio

May 08, 2024
Korean drug makers flock to obesity treatment

South Korea’s pharmaceutical companies are accelerating the development of anti-obesity drugs to take share in the rapidly growing market, which is estimated to hit $100 billion by 2030. Hanmi Pharmaceutical is one of a few Korean drug companies that have been pushing ahead with their clinical tr...
May 02, 2024
Celltrion seeks bigger footing in South America

Celltrion announced Thursday that the company has won public tenders in Peru to provide its autoimmune disease treatment Remsima (infliximab) and anticancer product Herzuma (trastuzumab) to the South American country. According to Celltrion, Remsima has won a tender held by the Peruvian Workers' I...
April 29, 2024
Celltion’s Zymfentra gets preference in top US formulary

Korean biosimilar giant Celltrion said Monday that its Zymfentra, the world’s first subcutaneous formulation of infliximab called Ramsima SC outside the US, has been included in the preferred formulary of Express Scripts, one of the top three pharmacy benefit managers or PMBs in the US. In the US...
April 25, 2024
LG Chem eyes new leap into top science company

LG Chem, South Korea's leading chemical company, unveiled Thursday a new vision to transform into a global top-tier science company, centering on its three business pillars -- electric mobility, sustainable materials and pharmaceuticals. Under the new vision, it has set an ambitious goal of reachi...
April 25, 2024
Samsung Biologics Q1 earnings hit all-time high

Samsung Biologics, a leading contract development and manufacturing organization, announced Wednesday that the company’s earnings in the first quarter this year hit an all-time high. In the January-March period, Samsung Biologics’ sales increased by 31.3 percent on-year to 946.9 billion won ($69...
April 23, 2024
Celltrion sees market share of Remsima rising in European nations

Celltrion saw the combined market share of its autoimmune biosimilar infliximab products, Remsima and Remsima SC, rising in five European nations, company officials said Tuesday. The combined market share of Remsima and the subcutaneous version of the drug hit 74 percent in Britain, Germany, Franc...
April 05, 2024
Samsung Bioepis begins phase 3 clinical study for its Keytruda biosimilar

Samsung Bioepis, Samsung Group’s biosimilar arm, announced Friday that the company had started a phase 3 clinical study for SB27, a Keytruda biosimilar. Keytruda is an immuno-oncology drug developed by MSD, a US multinational pharmaceutical company. Indications for the drug include non-small cell...
April 01, 2024
Pharmaceutical rivals partner for Fexuclue's sales

Daewoong Pharmaceutical has partnered with Chong Kun Dang for local sales of the gastroesophageal reflux disease (GERD) treatment Fexuclue, the country’s 34th new drug, the company said Monday. Fexuclue is a potassium-competitive acid blocker (P-CAB)-based GERD treatment that is designed to impro...
April 01, 2024
Samsung Bioepis launches half-priced Soliris biosimilar

Samsung Bioepis, a biosimilar developer under Samsung Group, announced Monday that the company decided to launch its Soliris biosimilar Epysqli in Korea at a price nearly 50 percent cheaper than the original drug. Epysqli is a biosimilar referencing Soliris, a high-cost drug for the treatment of r...
April 01, 2024
Hanmi heirs may seek to repair with family first

The management conflict within the founding family of Hanmi Pharmaceutical Group ended, as the sons of founder Lim Sung-ki -- Lim Jong-yoon and Lim Jong-hoon -- secured a majority within Hanmi Science’s board at the general meeting of shareholders last week. However, there are still multiple hurdl...
April 01, 2024
Kolmar Korea makes R&D push for bigger footing globally

The global rise in popularity of K-beauty brands has brought attention to Kolmar Korea, a leading cosmetics original design manufacturer that has secured a whopping 70 percent market share in the sun care sector alone here. According to the company Sunday, its “Fitting SPF Boosting” technology h...
March 28, 2024
Hanmi-OCI merger called off

The expected merger between OCI Group and Hanmi Group has been called off after a general meeting of shareholders at Hanmi Science, the holding company of Korea's leading drug firm Hanmi Pharmaceutical, on Thursday. The management conflict within the founding family has also temporarily ended as L...
March 28, 2024
Korea’s CMO ramp-up lures biotech investors

South Korea’s growing biopharmaceutical production capacity is increasingly making the country an attractive investment destination for global life science companies, industry sources said Thursday. Since 2016, global pharmaceutical and biotech firms started building their research and developmen...
March 28, 2024
Trade ministry, US bio firm Thermo Fisher discuss investment

The trade ministry said Thursday it has discussed a possible investment opportunity in South Korea with a major US biotechnology firm, as the country aims to become a global manufacturing hub in the industry. Trade Minister Cheong In-kyo met Mark Smedley, a senior vice president of Thermo Fisher S...
March 25, 2024
SK bioscience devises new business strategy for post-pandemic era

SK bioscience, a pharmaceutical affiliate under South Korea's SK Group, on Monday unveiled its latest strategic initiative, aimed at preparing for possible pandemics in the future and expanding into emerging sectors in the post-COVID-19 era. The new strategy, dubbed SKBS 3.0 Reboot, focuses on bro...

1 2 3 4 5 6

EDITOR'S PICKS

Herald Corporation |CEO : Choi Jin-Young |Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea |Title : The Investor |Date of registration : 2016.06.21 |Date of issue : 2016.06.21
Publisher. Editor : Choi Jin-Young |Chief Privacy Officer & Juvenile Protection Manager : Choi He-suk |T +82-2-727-0021 |E investor@heraldcorp.com

FAMILY SITE GO

Company Registration No. 104-81-06004 |Mail-Order Business Registration 2016 - Seoul Yongsan - 00590 |Business info |Gov’t registration No. Seoul 아04099